Today (March 28), the Campaign for Tobacco-Free Kids launched a new advertising initiative, “End the Formula,” ahead of the May 3 Miami Grand Prix, calling on Formula 1 to eliminate all tobacco-related sponsorships. The campaign targets partnerships between major F1 teams and companies, including Philip Morris International and British American Tobacco, which promote nicotine pouch and e-cigarette brands such as Zyn, Velo, and Vuse through branding on cars, driver apparel, and digital media. The campaign ties into similar efforts that began in March, which included ads, coordinated outreach with 162 organizations across 57 countries, and more than 25,000 petition messages urging F1 and affiliated partners to end these sponsorship arrangements.
Tag: Zyn
-
Philippines Advocates Alleging Violations from Zyn, IQOS
Anti-smoking groups in the Philippines are calling on the Department of Trade and Industry (DTI) to act on complaints alleging violations of the Vape Regulation Act of 2022 by brands including Zyn and IQOS, according to the Sun Star. Advocacy organizations claim the products were promoted at public events such as the Sinulog Festival and through collaborations with artists, which they say are prohibited under the law that bans sponsorships and celebrity endorsements tied to nicotine products.
Additional concerns were raised over product compliance, with some groups alleging that Zyn nicotine pouches are being sold without proper registration. The DTI, which has jurisdiction over vape-related regulation, is being urged to investigate and enforce existing rules, as advocates warn that continued non-compliance could increase youth exposure and undermine public health protections.
-
PM Plans Zyn Expansion in Tokyo
Philip Morris Japan announced it plans to expand sales of its oral nicotine pouch product “Zyn by IQOS” in Tokyo, with a broader rollout beginning May 11 across IQOS stores and convenience retailers. The product will be offered in Cool Mint, Spear Mint, Apple Mint, and Peach flavors, each with “low” and “medium” strength options. The company said the expansion reflects growing demand for discreet, smoke-free alternatives that can be used in a wider range of settings.
-
PMI Reduces Zyn Production in Owensboro
Philip Morris International announced it will scale back production at its Swedish Match facility in Owensboro, Kentucky, shifting part of its Zyn nicotine pouch operations from a 24/7 schedule to a 24/5 schedule beginning in early July, according to The Owensboro Times. The adjustment primarily affects the Zyn Flagship department, which will return to a five-day, three-shift model under the terms of the existing collective bargaining agreement.
The company said the move reflects changing market conditions, with production currently exceeding demand following a period of rapid growth and capacity expansion. PMI invested more than $230 million into the Owensboro site in 2024, increasing output and adding approximately 450 jobs to support strong demand for Zyn products.
PMI emphasized that the change is a production realignment rather than a reduction in long-term commitment to the facility, noting that other operations, including Zyn Ultra production and maintenance, will remain on a 24/7 schedule. The company said it will work with union leadership on staffing adjustments and indicated the schedule could return to continuous operations if demand increases.
-
PMI Expands Ducati Partnership to Promote Zyn
Philip Morris International expanded its long-standing partnership with Ducati Corse, announcing that its Zyn nicotine pouch brand will be featured on MotoGP race liveries at select events starting in the 2026 season. The move marks a new phase in the collaboration, which dates back to 2003, and reflects PMI’s continued focus on promoting smoke-free products through high-profile global platforms.
PMI said the partnership aligns with its broader strategy to grow its oral nicotine portfolio, with ZYN positioned as a key driver in the company’s transition away from cigarettes. Ducati said the renewed agreement builds on a shared emphasis on innovation and performance, as both organizations look to extend their presence and engagement with adult consumers in international markets.
-
PMI to Double Zyn Investment in Ukraine
Philip Morris International said it plans to invest $10 million in 2026 to expand the nicotine pouch category in Ukraine and launch a new line of Zyn, following a $5 million investment in 2025. According to Interfax Ukraine, the company said funds will support portfolio expansion, infrastructure, and adult consumer awareness. The new “dry” pouches contain no water or glycerin, are smaller, less flavored, and range from 1.5 mg to 6 mg nicotine across nine SKUs. Initial supply will be imported from Sweden.
The company estimates nicotine pouches in Ukraine could grow 20% annually. PMI cited Zyn’s U.S. marketing authorization from the U.S. Food and Drug Administration as supporting further investment. PMI reported that smoke-free products were available in 105 markets at the end of 2025, used by 43 million adult consumers, and accounted for 41.5% of net revenue.
-
FDA’s Pouch Fast-Track Scheme Stalling Over Youth Worries
A fast-track review program at the U.S. Food and Drug Administration aimed at accelerating authorizations for nicotine pouch products has stalled, as agency scientists weigh concerns about youth uptake and risks to non-users against potential harm-reduction benefits for smokers, according to sources cited by Reuters. Reuters said applications tied to pouch brands from Philip Morris International (Zyn) and British American Tobacco (Velo) remain under review despite expectations that decisions would be made by the end of 2025 under the pilot scheme. The FDA has already authorized six products under Altria Group’s on! brand, but reviewers are said to be taking a more cautious stance on other applications where evidence of net public-health benefit is viewed as less clear-cut.
While FDA data shows pouch use among middle- and high-school students remains relatively low, it has been rising, prompting heightened scrutiny. Tobacco companies argue the pilot program is critical for restoring legal market competition amid a surge of unregulated products, while public-health advocates warn that rapid authorizations could fuel new addiction trends. The FDA said decisions continue to be guided by science and statutory standards rather than external pressure.
-
Health Groups Call for F1 to Cut Ties with Pouch Sponsors
Campaign for Tobacco Free Kids said that 160 public health and advocacy groups from 57 countries have urged Formula One to extend its ban on tobacco sponsorships to include nicotine pouches, warning that current team partnerships with Philip Morris International and British American Tobacco, promoting Zyn and Velo through Ferrari and McLaren, make branding visible to millions of young fans. In a letter to F1 CEO Stefano Domenicali, the groups said the sponsorships undermine the sport’s youth-focused expansion efforts and expose minors to addictive nicotine products, citing data that a significant share of F1’s social media audience is under 25. Separate letters were also sent to The Walt Disney Company, The Lego Group, and Mattel, calling on them to support a comprehensive prohibition on all tobacco-related sponsorships in the sport.
-
PMI Ramps Up Zyn Production in New Colorado Plant
Philip Morris International said it has launched “large-scale production” of its ZYN nicotine pouches at a new 600,000-square-foot facility in Aurora, Colorado, representing a $600 million investment as U.S. demand for oral nicotine products accelerates. The plant, which began limited production in September 2025 as construction continued, is expected to generate more than $1 billion in economic contributions for the Denver-area suburb as it becomes fully operational in 2026, will host at least 500 full-time employees, and generate upward of $550 million annually in economic benefits statewide.
-
Nicotine Pouch Growth Drives Haypp’s 5% Sales Increase
Haypp Group reported strong global growth in nicotine pouches (NPs), with Q4 2025 volume up 28%, driven by the U.S. reintroduction of Zyn in September 2025 and accelerating growth in the UK. NPs now account for 67% of total volume, with FY25 volume up 13% year-over-year. U.S. consumer offtake rose approximately 35% in Q4 2025 and January 2026 volumes jumped 120% year-over-year, with new customer acquisition up over 250%. The company cited improved retention through localized teams, research, and consumer-focused initiatives, achieving an all-time high Net Promoter Score of 82. In the UK, Q4 2025 volume rose 73% and new customer growth reached 112%, accelerating to ~200% and ~125%, respectively, in January.
Looking ahead, Haypp anticipates regulatory changes in Austria will force an exit by mid-2026, though this market represents less than 1% of total sales. The company strengthened its U.S. infrastructure, increasing overhead by 29% to support Media and Insights and online growth initiatives. Leverage stood at 0.6x net debt/adjusted EBITDA at year-end, with inventory tactically increased ahead of January 2026 price hikes. Haypp’s Board reaffirmed 2028 targets: 18–25% annual revenue growth, an adjusted EBIT margin of 5.5% ±150 bps, and reinvestment of cash flows to support ongoing expansion in its core U.S. and UK markets while maintaining compliance as a competitive advantage.